Sarepta Therapeutics (SRPT) Sank To A 2-Month Low On FDA News

The FDA reiterated its "Negative" outlook on eteplirsen Thursday, a treatment for patients with Duchenne muscular dystrophy developed by Sarepta Therapeutics (SRPT).

from RTT - Before the Bell http://ift.tt/1T2X6D9
via IFTTT